Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Lyell Immunopharma, Inc. (LYEL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 4 Klausner Richard (Director) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Sold 58,020 shares @ $2.28, valued at $132.3k
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 4 Lang Matthew (Chief Business Officer) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Granted 2,250,000 options to buy @ $2.31, valued at $5.2M
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023"
07/20/2023 3 Lang Matthew (Chief Business Officer) has filed a Form 3 on Lyell Immunopharma, Inc.
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/28/2023 4 Hill Stephen J. (Chief Technical Ops. Officer) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Granted 900,000 options to buy @ $2.13, valued at $1.9M
02/28/2023 4 Albertson Tina M. (Chief Medical Officer) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Granted 700,000 options to buy @ $2.13, valued at $1.5M
02/28/2023 4 Lee Gary K. (Chief Scientific Officer) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Granted 600,000 options to buy @ $2.13, valued at $1.3M
02/28/2023 4 Thompson Rahsaan (Chief Legal Officer) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Granted 245,000 options to buy @ $2.13, valued at $521.9k
02/28/2023 4 Newton Charles W. (CFO) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Granted 700,000 options to buy @ $2.13, valued at $1.5M
02/28/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5% stake in Lyell Immunopharma Inc.
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/12/2022 4 Thompson Rahsaan (Chief Legal Officer) has filed a Form 4 on Lyell Immunopharma, Inc.
Txns: Granted 715,000 options to buy @ $6.91, valued at $4.9M
10/06/2022 8-K Quarterly results
10/03/2022 3 Thompson Rahsaan (Chief Legal Officer) has filed a Form 3 on Lyell Immunopharma, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy